Navigation Links
First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
Date:4/22/2008

SAN JOSE, Calif., April 22 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a leading provider of medical devices for the minimally invasive treatment of peripheral vascular disease, explains interruption of its first-quarter 2008 teleconference and webcast held yesterday at 2:00 p.m. PT/5:00 p.m./ET. As a result of teleconference vendor communications difficulties, the Question-and-Answer period did not take place as planned.

Interested parties are encouraged to review the company's news release on its first-quarter 2008 financial results and to listen to either the telephonic replay (719-457-0820, code number 4678111) or audio webcast of the prepared remarks by management archived on the company's website at http://ir.vnus.com/. If anyone has questions, they're invited to contact the company at ir@vnus.com.

About VNUS Medical Technologies, Inc.

VNUS is a leading provider of medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that is often the underlying cause of painful varicose veins. VNUS sells the Closure(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. Approximately 300,000 patients have been treated to date with VNUS Closure catheters. For more information, please visit the corporate website at http://www.vnus.com .


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
2. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
3. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
4. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
5. Abbott Hosts Conference Call for First-Quarter Earnings
6. Cardinal Health To Announce First-Quarter Results on November 5
7. Quality Care, Not Number of Procedures, Determines Bypass Results
8. Allscripts to Announce First Quarter 2008 Results on April 30
9. CuraGen Reports First Quarter 2008 Financial Results
10. Albemarle Reports Record Quarterly Net Sales and Operating Results
11. Lincare Holdings Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... It is vital for any lab to secure funding, and the best ... Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline analysis and ... a GLP (Good Laboratory Practice) fashion. , With features designed to simplify life in ...
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward ... comments on social media that offer a rare glimpse into the mind of those ... and New York Times bestselling author, has described people with ADHD as having “Ferrari ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood associated ... appearing online in the journal Radiology. , Heart disease and brain disease exact a ... the rapidly aging population. Damage to both organs often occurs at a subclinical stage, ...
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Arcturus ... RNA medicines company, announced today that it entered ... develop RNA-based therapeutics for the treatment of NASH ... wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer ... "Given Takeda,s long-standing commitment to and expertise ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
(Date:12/6/2016)... new study released today by the Alliance for Integrity ... Pricing Program will continue to expand at an unprecedented rate ... $23 billion in total purchases at the 340B price. This ... B drug reimbursement purchases over the next five years.      ... data on total drug purchases through 340B from 2005 to ...
Breaking Medicine Technology: